Idactamab INT-001 represents an exciting medicinal approach for treating selected blood-related malignancies. The antibody shows a unique mode of action, particularly targeting CD-38, a cell-surface protein present widely on several blood-forming populations. Preliminary investigational studies seeking to assess this tolerability and power in patie

Carfilzomib is a novel proteasome inhibitor leveraged in the struggle against cancer. This treatment works by interfering with the activity of the proteasome, a cellular complex responsible for the breakdown of proteins. By inhibiting this process, carfilzomib results in the accumulation of damaged or abnormal proteins, ultimately triggering cell d

Tepotinib, also known as {MSC2156119|the developmental compound|this drug), represents a novel advance in the targeting of non-small cell lung cancer, particularly in those harboring MET exon 14 skipping. This targeted tyrosine kinase inhibitor|TKI shows remarkable effect against cancer expansion in preclinical research and first human research. It

Teclistamab stands as a revolutionary advanced anti-BCMA antibody drug construct, designated JNJ-64007957, featuring immense promise in the therapy of multiple myeloma. This innovative medication works by specifically targeting BCMA, a molecule highly expressed on the surface of myeloma cells. Through this specific mechanism, teclistamab administer